Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...
Benzinga.com11h
1MRK : Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under...
In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes ...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
The Pharma Letter6h
Subcutaneous Keytruda meets goals, says Merck
US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
Merck announces ‘positive’ results from Phase 3 MK-3475A-D77 trial
Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...
Monthly Prescribing Reference1d
SC Pembrolizumab Coformulation Noninferior to IV Formulation in NSCLC Trial
The phase 3 trial met both primary pharmacokinetic endpoints. Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death ...
Zacks.com on MSN1d
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...
EurekAlert!8d
Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with ... The trial was funded by by a ...
Medpage Today on MSN6d
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...